CNTGF (Centogene NV) 3-Year EBITDA Growth Rate: 0.00% (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTGF Centogene NV CNTGF
12 GF Score
Price $0.12
View Full Analysis

What is Centogene NV 3-Year EBITDA Growth Rate?

Centogene NV CNTGF 12 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2023. GuruFocus rates CNTGF with a GF Score™ of 12/100.

Centogene NV's EBITDA per Share for the six months ended in Dec. 2023 was $-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Centogene NV  (OTCPK:CNTGF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Centogene NV 3-Year EBITDA Growth Rate Related Terms

CNTGF vs ISPC, CHEK, FUNI: 3-Year EBITDA Growth Rate Comparison

For the Diagnostics & Research subindustry, Centogene NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centogene NV 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Centogene NV's 3-Year EBITDA Growth Rate falls into.


CNTGF
12GF Score
Centogene NV CNTGF
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Centogene NV 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Centogene NV (CNTGF) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2023. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Centogene NV and its competitors.
Is Centogene NV's 3-Year EBITDA Growth Rate too high?
Centogene NV's current 3-Year EBITDA Growth Rate is 0.00%. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's 3-Year EBITDA Growth Rate compare to ISPC and CHEK?
Centogene NV's 3-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median 3-Year EBITDA Growth Rate is 11.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.05, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Centogene NV and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centogene NV's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Centogene NV (CNTGF), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Centogene NV Business Description

Address Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score

Get the complete analysis for CNTGF

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price